How to appeal an Aetna lymphoma & leukemia (heme malignancies) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for lymphoma & leukemia (heme malignancies)

Cited policy: Aetna CPB Venclexta (Venetoclax) for CLL and AML

CLL: Ven+G 1L (CLL14), Ven+R r/r (MURANO), Ven monotherapy del(17p) salvage. AML: Ven+aza or Ven+LDAC unfit (age ≥75 OR HCT-CI ≥3 OR cardiac/pulm precluding intensive chemo). 5-week ramp-up (20→50→100→200→400 mg) with TLS prophylaxis (allopurinol, hydration, electrolyte monitoring). Hematologist Rx.

How Aetna denies lymphoma & leukemia (heme malignancies) — and how to counter it

Where Aetna pushes back: 1) AML — must try 7+3 first; 2) CLL — fixed-duration not preferred over indefinite BTKi; 3) Ramp-up monitoring inpatient not authorized; 4) Lab monitoring frequency excessive.

Counter-arguments that hold up: VIALE-A (DiNardo NEJM 2020;383:617) — Ven+aza vs aza alone in unfit AML, OS HR 0.66. NCCN AML v2.2024: 7+3 reserved for fit; unfit (age ≥75 / HCT-CI ≥3 / comorbidity) — Ven+aza is preferred standard. CLL14 (Fischer NEJM 2019;380:2225) — fixed-duration Ven+G 1L, deep MRD-negative responses, off-treatment durable remission. MURANO (Seymour NEJM 2018;378:1107) — Ven+R fixed-duration r/r CLL. TLS ramp-up monitoring is FDA-LABEL REQUIRED — denial of monitoring functionally denies the drug.

What Aetna typically denies for lymphoma & leukemia (heme malignancies)

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For lymphoma & leukemia (heme malignancies), expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the lymphoma & leukemia (heme malignancies) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Imbruvica
• Calquence
• Brukinsa
• Jaypirca / pirtobrutinib
• Venclexta
• Rituxan / rituximab

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.